.Attribute Medicine, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medicine conjugate (ADC) tisotumab vedotin led to boosted progression-free and general survival, resulting in FDA commendation as well as a brand new therapy choice for individuals.